Following the FDA ODD, European designation underscores ICT01’s potential as a ...

The landscape of cancer therapeutics is rapidly evolving with the emergence of sophisticated biologics designed to deliver highly targeted and potent ...

Multiple myeloma (MM) remains a complex and heterogeneous hematologic malignancy with evolving therapeutic challenges. In recent years, immunotherapy has ...